4D Molecular Therapeutics, Inc. - FDMT STOCK NEWS

4D Molecular Therapeutics (Nasdaq: FDMT) announced its participation in two upcoming investor conferences. The first is the Jefferies Cell and Genetic Medicine Summit, featuring a corporate presentation on September 30, 2022, at 9:00 a.m. ET. The second event is Chardan’s 6th Annual Genetic Medicines Conference, where one-on-one meetings will take place on October 3, 2022. A live audio webcast of the presentation will be accessible on the company's website, with a replay available for two weeks post-event. 4DMT specializes in targeted genetic medicines and is advancing five clinical-stage products in various therapeutic areas.

4D Molecular Therapeutics (Nasdaq: FDMT) reported its second quarter 2022 financial results, showing total revenue of $0.2 million, down from $14.6 million in Q2 2021. The company maintained $261.6 million in cash and equivalents, sufficient to fund operations into the first half of 2025. Key developments include the expansion of the eligible patient population for 4D-310's Phase 1/2 trial for Fabry disease to include females. The net loss for the quarter was $28.1 million, compared to $7.6 million in the prior year.

4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) has announced its participation in two major investor conferences. The company will present at the Jefferies 2022 Healthcare Conference on June 8, 2022, at 8:00 a.m. ET, followed by a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 15, 2022, at 8:40 a.m. PT. Investors can access a live audio webcast of these presentations on their website, with replays available for two weeks.

4DMT is focused on targeted genetic medicines using its Therapeutic Vector Evolution platform.

4D Molecular Therapeutics (NASDAQ: FDMT) reported its first quarter 2022 financial results, highlighting key clinical advancements in its pipeline. The firm initiated the treatment of the first patient with 4D-150 for wet AMD and dosed the first patient in a Phase 1/2 trial for 4D-710 targeting cystic fibrosis. Despite these developments, total revenue decreased to $1.2 million from $2.0 million year-over-year. R&D expenses rose to $19.4 million, contributing to a net loss of $26.3 million. The company maintains a strong cash position of $284.5 million, expected to fund operations into 2024.

4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) will participate in the 2022 Bank of America Healthcare Conference on May 10, 2022, at 8:40 a.m. PT. The event will feature a fireside chat, accessible via a live audio webcast on the 4DMT website. This clinical-stage biotherapeutics company focuses on genetic medicines and has developed targeted vectors for five clinical products addressing diseases in ophthalmology, cardiology, and pulmonology, including Fabry disease and cystic fibrosis.

4D Molecular Therapeutics (Nasdaq: FDMT) has initiated its Phase 1/2 clinical trial for 4D-710, focusing on treating cystic fibrosis. The first patient has been dosed, marking a significant milestone for the company. This therapy aims to deliver CFTR expression to lung cells, potentially benefiting a wide range of cystic fibrosis patients, especially those unable to use existing treatments. The trial will assess safety, tolerability, and clinical activity, with around 18 patients expected to participate.

4D Molecular Therapeutics (Nasdaq: FDMT) reported 2021 financial results with total revenue of $18 million, up from $13.6 million in 2020, driven by a Roche collaboration. The company provided clinical data updates on three key programs, including 4D-310 for Fabry disease, showing promising results. Two additional programs have entered clinical development. The company ended 2021 with $315 million in cash, expected to fund operations through mid-2024. Despite increased R&D and G&A expenses, the net loss grew to $71.3 million from $56.7 million in 2020.

On February 22, 2022, 4D Molecular Therapeutics (Nasdaq: FDMT) announced the resignation of Professor David Schaffer, Ph.D., from its board of directors. This transition comes as the company evolves into a clinical-stage gene therapy firm, with five products currently in development. Professor Schaffer, who has served on the board since 2013, is taking up new roles at UC Berkeley, while emphasizing the company’s strengthened board with new independent directors. 4DMT aims to leverage its Therapeutic Vector Evolution platform for gene therapy innovations in ophthalmology, cardiology, and pulmonology.

4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company, announced participation in the 11th Annual SVB Leerink Global Healthcare Conference, scheduled for February 16, 2022, at 2:00 p.m. PT. The event will take the form of a fireside chat, and a live audio webcast will be accessible through the company’s website, with a replay available for two weeks post-event. 4DMT focuses on targeted gene therapies, currently developing five clinical-stage products for conditions including Fabry disease, wet AMD, and cystic fibrosis.